Suresh Senan

Suresh Senan is Professor of Clinical Experimental Radiotherapy and Head of Thoracic Oncology Radiotherapy at Amsterdam UMC, Vrije Universiteit Amsterdam, where he has established one of the world's leading programs in stereotactic ablative radiotherapy (SABR) and stereotactic body radiotherapy (SBRT) for thoracic malignancies. He is recognized internationally as a pioneer in the clinical development and international dissemination of SABR for early-stage non-small cell lung cancer (NSCLC), oligometastatic disease, and centrally located lung tumors, and has led or co-led landmark randomized trials that have established SABR as the standard of care for medically inoperable early-stage lung cancer. Senan led the STARS and ROSEL trials comparing surgery with SABR for operable early-stage NSCLC, and was instrumental in the pooled analysis of these trials that first demonstrated comparable survival outcomes between SABR and lobectomy—data that catalyzed a global reassessment of surgical versus radiation approaches in early lung cancer. He has also led the PACIFIC-like Dutch trials integrating immune checkpoint inhibitors with consolidation radiotherapy in locally advanced NSCLC, and has been a principal investigator on the STEREOSABR, SARON, and COMET trials evaluating SABR for synchronous and metachronous oligometastatic disease across tumor histologies. Beyond lung cancer, Senan has championed the use of MRI-guided SBRT delivery to improve targeting accuracy for central lung and mediastinal targets where proximity to heart, great vessels, and bronchi demand sub-millimeter precision. He has contributed to international consensus guidelines on SABR target delineation, dose prescriptions, and normal tissue constraints published through ESTRO and IASLC. His editorial contributions to Radiotherapy and Oncology and the Journal of Thoracic Oncology, combined with his teaching at ESTRO schools, have disseminated SABR expertise globally. He is widely regarded as one of the most impactful clinical radiation oncologists of his generation in thoracic oncology.